Mochida To Increase Sales To ¥89 Billion By 2012
This article was originally published in PharmAsia News
Mochida Pharmaceutical announced a three-year plan to increase sales by ¥4.5 billion to ¥78 billion by 2012
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.